Moderna Up 109% YTD: Cramer Calls It Investable—Is It a Buy on the Dip?
Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
Finance entity
Moderna Inc.
Company MRNACoverage clusters in markets, which accounts for 2 of those 3, with the remainder spread across 1 other category. AlphaCore Wealth Advisory is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window.
Last mentioned: Jul 21, 2026
Entity pulse
Recent coverage · Moderna Inc.
↑
3 stories
avg impact
33% positive
33% negative
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
What the coverage shows about Moderna Inc.
Coverage clusters in markets, which accounts for 2 of those 3, with the remainder spread across 1 other category. AlphaCore Wealth Advisory is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window. That works out to roughly 0.2 stories per week across a 128-day span. At 6.3, the average consequence score sits below the same-window beat average of 6.4. Moderna Inc. appears in 3 tracked Finance stories published from March 16, 2026 through July 21, 2026.
- Stories tracked
- 3
- Per week
- 0.2
- Sources per story
- 2
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 1701 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Moderna Inc.. Shared-story counts are live from our verified record — not editorial picks.
Key Data
Timeline
-
Industry Warning
Editorials warn that erratic FDA behavior is a threat to biotech innovation.
-
Refusal to File
FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application.
-
Regulatory Alignment
FDA officials reportedly signal support for Moderna's trial data workaround.
-
Grant Rescission
The federal government rescinds hundreds of millions in mRNA research funding.
-
Peak Valuation
Moderna reaches a market capitalization of $200 billion during the pandemic height.
Stories mentioning Moderna Inc. 3
S&P 500 Ends Lower: Chips -5.3%, Moderna +13%, Inflation Above 4%
A volatile session saw the S&P 500 close marginally lower as a 5.3% chip sell-off collided with a 13% Moderna rally. With May inflation topping 4%, the Fed's next move remains a key market driver.
FDA Regulatory Shift Threatens Biotech Innovation and Moderna's Recovery
Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment.
Moderna Inc. is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.